Core Insights - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [2] Company Overview - Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] - The company is developing a pipeline of wholly owned drug product candidates aimed at improving the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [2] Upcoming Events - Steve Ledger, the CEO of Serina, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025, with his discussion set for July 29, 2025, at 2:00 p.m. ET [1]

Core Insights - Serina Therapeutics is making significant progress in developing its proprietary POZ Platform for drug optimization, particularly focusing on SER-252 for advanced Parkinson's care [2][3] - The company has secured $15 million in equity financing, enhancing its financial foundation to support ongoing clinical trials and research initiatives [7] - Recent data presented at a summit indicates that Serina's POZ-lipid technology may lead to safer and more effective lipid nanoparticle formulations for gene therapy [7] Recent Highlights - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 by Q4 2025 [6] - Two experienced biotech leaders have been added to the Board of Directors, enhancing corporate strategy and business development capabilities [7] - The POZ Platform is being advanced across multiple therapeutic modalities, including neurological disorders and RNA-based therapeutics [2][7] First Quarter Operating Results - Revenues for Q1 2025 were not material, similar to Q1 2024 [4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, driven by higher R&D and administrative costs [4][6] - R&D expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, primarily due to increased headcount and professional fees [5] Financial Performance - The net loss for Q1 2025 was $4.8 million, or $(0.49) per share, compared to a net loss of $15.0 million, or $(5.38) per share, in Q1 2024 [10][22] - Other income for Q1 2025 was $1.0 million, a significant improvement from a net expense of $12.7 million in Q1 2024 [9][22] - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025 [11] Liquidity Information - The company has a strengthened balance sheet following recent financing, which includes a $10 million investment from JuvVentures and a $5 million private placement [7][11] - Total current assets as of March 31, 2025, were $5.8 million, with total liabilities at $5.2 million [20][21]

Core Insights - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing its proprietary POZ Platform™ for drug optimization [2] - The company is set to present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT [1] Company Overview - Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] - The company is developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other indications [2] - The POZ Platform™ has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [2]

Core Insights - Serina Therapeutics, Inc. has successfully closed a $5 million financing round from strategic shareholders to support the development of its lead clinical candidate SER-252 for Advanced Parkinson's disease [1][2] - The company plans to initiate a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025, indicating a strong commitment to advancing its clinical pipeline [1][2] Financing Details - The financing involved the issuance of 965,250 shares of convertible preferred stock at a price of $5.18 per share, which aligns with the closing price of its common stock on April 7, 2025 [2] Product Overview - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [3] - The product utilizes Enable Injections' enFuse™ wearable drug delivery platform, enhancing patient comfort through easy administration via long-acting subcutaneous injection [3] Technology Platform - Serina's proprietary POZ Platform™ is based on a synthetic polymer that allows for better control in drug loading and precision in drug release rates [4] - The POZ technology aims to improve the pharmacokinetic profiles of existing drugs, potentially addressing issues like toxicity and short half-life [4] Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [5] - The company is headquartered in Huntsville, Alabama, and is positioned to leverage its POZ Platform™ across various therapeutic modalities [5]

Core Points - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing its proprietary POZ Platform™ for drug optimization [3] - The CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025 [1] - The company is headquartered in Huntsville, Alabama, and is developing a pipeline of drug candidates for neurological diseases and other indications [3] Company Overview - Serina Therapeutics is developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other conditions [3] - The POZ Platform™ has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [3] - The company operates from the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama [3] Event Information - A live webcast of the CEO's presentation will be available for registered attendees, with an archived replay accessible for 90 days post-event [2]